September 22, 2022
Pfizer Japan plans to discontinue the sale of the capsule versions of its breast cancer treatment Ibrance (palbociclib) around June 2023, the company said in a notice to healthcare providers. The move comes as demand for Ibrance Capsules 25 mg/125...read more